127 / 1498
Random. Phase III (AETHERA)
BV in HL pts
after auto-TX
.
N = 322 HL post ASCT
high risk (no CR, r/r <12 mo, ex-nodal)
Brentuximab vedotin 1.8 mg/kg q3wk
SCREENING
28 days
TREATMENT PHASE
16 three-wk cycles
FOLLOW-UP
Every 12 wk
Assessments: 3, 6, 9, 12, 18, 24 mo, then every 6 mo
Follow-up: every 12 wk until death
Placebo q3wk